Cas no 7699-39-0 (procainamide hydrochloride)

Procainamide hydrochloride is a pharmaceutical compound primarily used as an antiarrhythmic agent to treat cardiac dysrhythmias. Its chemical structure, derived from procaine, features an amide group that enhances stability and prolongs its therapeutic action compared to ester-based analogs. The hydrochloride salt form ensures improved solubility in aqueous solutions, facilitating intravenous or oral administration. Procainamide hydrochloride exhibits Class IA antiarrhythmic activity, effectively blocking sodium channels and stabilizing myocardial cell membranes. Its predictable pharmacokinetics and well-characterized electrophysiological effects make it a reliable option for acute and chronic arrhythmia management. The compound is also utilized in diagnostic applications, such as during electrophysiological studies, due to its ability to provoke and assess arrhythmia mechanisms.
procainamide hydrochloride structure
procainamide hydrochloride structure
Product Name:procainamide hydrochloride
CAS No:7699-39-0
MF:C13H22ClN3O
MW:271.786282062531
CID:983091
PubChem ID:66068
Update Time:2025-05-20

procainamide hydrochloride Chemical and Physical Properties

Names and Identifiers

    • procainamide hydrochloride
    • 4-AMINOBENZOIC ACID 2-DIETHYLAMINOETHYLAMIDE HYDROCHLORIDE
    • PROCAINAMIDE HCL
    • PROCAINAMIDE HCL,BP
    • PROCAINE AMIDE HYDROCHLORIDE
    • procaineamideHClusp
    • procaineamidehydrochlorideusp
    • USP
    • Amidoprocaine
    • MLS001148635
    • Tox21_500995
    • PROCAINAMIDE HYDROCHLORIDE (USP-RS)
    • Procainhydrochlorid
    • 4-Amino-N-[2'-(diethylamino)ethyl]benzamide hydrochloride
    • NCGC00094291-03
    • CHEMBL605
    • Procapan
    • Opera_ID_1543
    • SR-01000000022-6
    • VU0239777-5
    • DTXSID2049422
    • Benzamide, p-amino-N-(2-(diethylamino)ethyl)-, hydrochloride
    • p-Amino-N-(2-(diethylamino)ethyl)benzamide monohydrochloride
    • Pronestyl-Sr
    • Procardyl hydrochloride
    • Novocamid hydrochloride
    • 4-amino-N-[2-(diethylamino)ethyl]benzamide hydrochloride
    • P-AMINO-N-(2-(DIETHYLAMINO)ETHY)BENZAMIDE MONOHYDROCHLORIDE
    • AKOS008056264
    • PROCAINAMIDE HYDROCHLORIDE [EP MONOGRAPH]
    • MFCD00012998
    • Benzamide, 4-amino-N-(2-(diethylamino)ethyl)-, monohydrochloride
    • P 9391
    • CAS-614-39-1
    • PROCAINAMIDE HYDROCHLORIDE [VANDF]
    • p-Amino-N-(2-(diethylamino)ethyl)benzamide hydrochloride
    • 4-Aminobenzoic acid 2-diethylaminoethylamide
    • PROCAINAMIDE HYDROCHLORIDE [MI]
    • Procanbid
    • 4-Aminobenzoesaeure-2-diethylaminoethylester hydrochlorid
    • DTXCID1029382
    • Tox21_202855
    • Z104477706
    • PROCAINAMIDE HYDROCHLORIDE (MART.)
    • FT-0603493
    • MLS000069436
    • SI4064O0LX
    • BCP28404
    • SW196878-3
    • BIM-0050968.0001
    • 4-amino-N-(2-diethylamino-ethyl)-benzamide HCl
    • NSC-757279
    • Hydrochloride, Procainamide
    • 4-Amino-N-(2-diethylaminoethyl)benzamide monohydrochloride
    • PROCAINAMIDE HYDROCHLORIDE (USP MONOGRAPH)
    • Procainii chloridum
    • SR-01000000022-2
    • NSC27461
    • NCGC00261680-01
    • Procainamidi hydrochloridum
    • ABTXGJFUQRCPNH-UHFFFAOYSA-N
    • PROCAINAMIDE HYDROCHLORIDE [JAN]
    • Procainamide hydrochloride [USP:JAN]
    • EN300-20309
    • PROCAINAMIDI HYDROCHLORIDUM [WHO-IP LATIN]
    • HY-A0084
    • LP00995
    • Procainamide (hydrochloride)
    • Q27108080
    • Procan
    • CCG-39233
    • Pronestyl hydrochloride
    • EINECS 210-381-7
    • Procan SR
    • Benzamide, 4-amino-N-(2-(diethylamino)ethyl)-, hydrochloride (1:1)
    • PROCAINAMIDE HCI
    • W-105155
    • Procainamide hydrochloride, European Pharmacopoeia (EP) Reference Standard
    • PROCAINAMIDE HYDROCHLORIDE [USP MONOGRAPH]
    • AMY22225
    • Procapan hydrochloride
    • 614-39-1
    • Cardiorytmin
    • 4-Amino-N-(2-(diethylamino)ethyl)benzamide monohydrochloride
    • Promide hydrochloride
    • Procainamide hydrochloride (JP17/USP)
    • Procainamide hydrochloride, >=98% (HPLC)
    • Procanbid (TN)
    • CCRIS 7143
    • NS00079626
    • Procainamide hydrochloride, United States Pharmacopeia (USP) Reference Standard
    • Procan SR (TN)
    • Benzamide, 4-amino-N-[2-(diethylamino)ethyl]-, monohydrochloride
    • 4-AMINO-N-(2-(DIETHYLAMINO)ETHYL)BENZAMIDE MONOHYDROCHLORIDE [WHO-IP]
    • NCGC00094291-02
    • PROCAINAMIDE HYDROCHLORIDE [WHO-DD]
    • Pharmakon1600-01500503
    • Procainamide hydrochloride (USP:JAN)
    • Procainamide hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
    • s4294
    • D00477
    • PROCAINAMIDE HYDROCHLORIDE [ORANGE BOOK]
    • HMS1569C15
    • NC00535
    • NSC 757279
    • PROCAINAMIDE HYDROCHLORIDE [WHO-IP]
    • SMR000059079
    • Pronestyl (TN)
    • PROCAINAMIDEHYDROCHLORIDE
    • EU-0100995
    • CHEBI:8429
    • SR-01000000022
    • NCGC00094291-04
    • PROCAINAMIDE HYDROCHLORIDE [MART.]
    • Procamide hydrochloride
    • PROCAINAMIDE HYDROCHLORIDE [USP-RS]
    • 4-Amino-N-(2-(diethylamino)ethyl)benzamide hydrochloride
    • 7699-39-0
    • Epitope ID:140114
    • F0850-6742
    • Supicane amide hydrochloride
    • Procan-SR hydrochloride
    • NCGC00260401-01
    • NSC757279
    • Procainamide hydrochloride, purum, >=98.0% (AT)
    • SPECTRUM1500503
    • KS-5258
    • AC-7552
    • NCGC00094291-05
    • HMS1920L04
    • 4-amino-N-[2-(diethylamino)ethyl]-Benzamide hydrochloride
    • PROCAINAMIDE HYDROCHLORIDE (EP MONOGRAPH)
    • D97622
    • 4-amino-N-[2-(diethylamino)ethyl]benzamide;hydrochloride
    • Pronestyl
    • NCGC00094291-01
    • SCHEMBL40758
    • 4-Amino-N-(2-diethylaminoethyl)benzamide hydrochloride
    • UNII-SI4064O0LX
    • 4-Amino-N-(2-diethylaminoethyl)benzamide HCl
    • DB-053889
    • Inchi： 1S/C13H21N3O.ClH/c1-3-16(4-2)10-9-15-13(17)11-5-7-12(14)8-6-11;/h5-8H,3-4,9-10,14H2,1-2H3,(H,15,17);1H
    • InChI Key： ABTXGJFUQRCPNH-UHFFFAOYSA-N
    • SMILES： Cl.O=C(C1C=CC(=CC=1)N)NCCN(CC)CC

Computed Properties

  • Exact Mass: 271.14500
  • Monoisotopic Mass: 271.1451400g/mol
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 3
  • Hydrogen Bond Acceptor Count: 3
  • Heavy Atom Count: 18
  • Rotatable Bond Count: 6
  • Complexity: 221
  • Covalently-Bonded Unit Count: 2
  • Defined Atom Stereocenter Count: 0
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • Topological Polar Surface Area: 58.4?2

Experimental Properties

  • Melting Point: 165-168?°C
  • PSA: 58.36000
  • LogP: 3.11450

procainamide hydrochloride Security Information

  • WGK Germany：3
  • Hazard Category Code： 22-36/37/38
  • Safety Instruction： S26; S36
  • RTECS：CV2295000
  • Hazardous Material Identification： Xn
  • HazardClass：IRRITANT
  • Risk Phrases：R22; R36/37/38

procainamide hydrochloride Customs Data

  • HS CODE：2922499100
  • Customs Data：

    China Customs Code:

    2922499100

procainamide hydrochloride Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
Crysdot LLC
CD12032479-5g
4-Amino-N-(2-(diethylamino)ethyl)benzamide hydrochloride
 7699-39-0 97%
5g
 $317 2024-07-24
Crysdot LLC
CD12032479-10g
4-Amino-N-(2-(diethylamino)ethyl)benzamide hydrochloride
 7699-39-0 97%
10g
 $564 2024-07-24

procainamide hydrochloride Related Literature

Additional information on procainamide hydrochloride

Procainamide Hydrochloride: A Comprehensive Overview

Procainamide hydrochloride, with the CAS number 7699-39-0, is a well-known antiarrhythmic agent that has been extensively studied and utilized in the medical field. This compound is primarily used for the management of various arrhythmias, particularly ventricular arrhythmias. Its chemical structure, which includes a benzene ring and a piperidine moiety, contributes to its unique pharmacological properties.

Recent studies have highlighted the importance of procainamide hydrochloride in the treatment of refractory arrhythmias, where traditional therapies may fail. Researchers have explored its mechanism of action in greater depth, revealing that it works by stabilizing the myocardial cell membrane and reducing automaticity. This effect is achieved through its ability to inhibit sodium channels and promote potassium efflux, thereby modulating cardiac electrical activity.

The pharmacokinetics of procainamide hydrochloride have also been a focus of recent investigations. Studies have shown that it undergoes extensive metabolism in the liver, with major metabolites including N-acetylprocainamide (NAPA) and (proc)-5-aminopentanoic acid (PAPA). These findings are crucial for understanding its therapeutic window and potential drug-drug interactions.

In terms of clinical applications, procainamide hydrochloride has demonstrated efficacy in both acute and chronic arrhythmia management. It is often administered intravenously for rapid control of life-threatening arrhythmias, while oral formulations are used for long-term maintenance therapy. Recent clinical trials have compared its effectiveness with newer antiarrhythmic agents, such as dronedarone and ivabradine, providing valuable insights into its role in contemporary cardiology practice.

One area of ongoing research involves the optimization of dosing regimens for procainamide hydrochloride to minimize adverse effects while maximizing therapeutic benefits. Studies have explored the use of loading doses versus maintenance doses, as well as the impact of patient-specific factors such as age, kidney function, and comorbidities on drug response.

The safety profile of procainamide hydrochloride remains a critical consideration. While it is generally well-tolerated, potential side effects include nausea, dizziness, and hypotension. Rare but serious adverse events include thrombocytopenia and lupus-like syndrome, which have been extensively studied to better understand their pathophysiology and management.

Recent advancements in molecular biology have shed light on the genetic factors influencing the response to procainamide hydrochloride. Polymorphisms in genes encoding sodium channels and drug-metabolizing enzymes have been identified as potential predictors of treatment outcomes, paving the way for personalized medicine approaches.

In conclusion, procainamide hydrochloride continues to be a valuable tool in the management of arrhythmias, supported by a robust body of evidence from both clinical and preclinical studies. As research progresses, particularly in areas such as pharmacogenomics and drug delivery systems, its role in cardiology is likely to evolve further.

7699-39-0 (procainamide hydrochloride) Related Products

Recommended suppliers
Zhengzhou Baoyu Pharmaceutical Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Zhengzhou Baoyu Pharmaceutical Co., Ltd.
ASIACHEM I&E (JIANGSU) CO., LTD
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
ASIACHEM I&E (JIANGSU) CO., LTD
Hubei Cuiyuan Biotechnology Co.,Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Hubei Cuiyuan Biotechnology Co.,Ltd
Shenzhen Jianxing Pharmaceutical Technology Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Shenzhen Jianxing Pharmaceutical Technology Co., Ltd.
SHOCHEM(SHANGHAI) CO.,lTD
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
SHOCHEM(SHANGHAI) CO.,lTD